Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT02071134

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry — Recruiting • Neurology • NCT02071134.

📅 14 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT02071134
Sponsor
Boston Scientific Corporation
Start
2014-03-04
ClinicaliQ Trial Snapshot
  • Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry — Recruiting • Neurology • NCT02071134.
  • Sponsor: Boston Scientific Corporation.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.

Eligibility Snapshot
  • Key Inclusion Criteria: * Meets criteria established in locally applicable Vercise System Direction for Use * At least 18 years old Key

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
Woman found out she had terminal brain cancer after suitcase fell on her head
Neurology · BBC Health · 13 Mar 2026
Lauren Macpherson was travelling home from a festival in London when her life changed forever. This update is most useful for patient…
View brief →
Guideline
2023 EAN Guidelines on the Management of Multiple Sclerosis
Neurology · 30 Mar 2026
This EAN guideline addresses 2023 EAN Guidelines on the Management of Multiple Sclerosis in Neurology. Use it to review current recommendation wording,…
View guideline →
Drug Science
CGRP Pathway — Migraine
Neurology · 04 Apr 2026
CGRP Pathway — Migraine is a clinically relevant Drug Science explainer. Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide predominantly expressed…
Explore mechanism →
Drug Science
Dopamine D2 Receptor
Mental Health / Psychiatry · 04 Apr 2026
Dopamine D2 Receptor is a clinically relevant Drug Science explainer. Dopamine (DA) is a monoamine neurotransmitter with distinct functional roles across four…
Explore mechanism →
Guideline
Parkinson’s Disease in Adults (NICE NG71)
Neurology · 27 Mar 2026
Start levodopa at low dose with titration based on response in patients with early motor symptoms, or use dopamine agonists (ropinirole/pramipexole) as…
View guideline →